Wayne, Pennsylvania-based Teleflex designed UroLift 2 to treat benign prostatic hyperplasia (BPH) symptoms in men with all prostate types up to 100g. Adding the ATC capabilities to the platform mark a significant advancement in BPH care, Teleflex said in a news release.
UroLift 2 provides an effective alternative to BPH medications and major surgery. Its adaptable design with ATC enables physicians to customize treatments to each patient’s unique anatomy. With a personalized approach, the system helps to maximize effectiveness, Teleflex says.
The company designed UroLift 2 ATC to offer enhanced confidence, improved control of obstructive tissue and targeting accuracy through tissue control wings and laser-etched needle markers. Its design makes tissue manipulation and implant delivery more precise. The system features a streamlined delivery system that uses one handle per procedure and individual implant cartridges. It ensures increased patient comfort and procedural efficiency, the company said.
According to Teleflex, UroLift 2 ATC allows for the treatment of a broader range of patients. The company says it opens new avenues for patient care.
“UroLift 2 ATC optimizes enlarged prostate treatment by providing urologists with unparalleled confidence and customization capabilities. The UroLift 2 System with ATC offers a comprehensive solution for BPH care, combining cutting-edge technology with proven clinical outcomes. Our innovative platform streamlines procedures and eliminates the need to transition between platforms during a procedure. Enhanced features, including greater and more consistent implant compression and reduced waste, will help drive outcomes and efficiency in healthcare delivery,” said Jake Newman, President, The Americas, Teleflex.
